Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP: DMTTF )

0.0509 -0.0015 (-2.86%)
Streaming Delayed Price Updated: 10:20 AM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,216
Open 0.0512
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0524
Today's Range 0.0509 - 0.0512
52wk Range 0.0500 - 0.3328
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion
This is the third article of a three-part series, you can find the first and 
Via Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga

Performance

YTD
-30.27%
-30.27%
1 Month
-32.13%
-32.13%
3 Month
-23.92%
-23.92%
6 Month
-60.85%
-60.85%
1 Year
-72.31%
-72.31%

More News

Read More
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
Via Benzinga
Small Pharma Inc: Positive Clinical Data For Major Depressive Disorder, Upcoming Virtual Roundtable
Via Benzinga
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
From Small Pharma Inc.
Via Globe NewsWire
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
From Small Pharma Inc.
Via Globe NewsWire
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
From Small Pharma Inc.
Via Globe NewsWire
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Via Benzinga
Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial
Via Benzinga
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
From Small Pharma Inc.
Via Globe NewsWire
Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents
Via Benzinga
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
From Small Pharma Inc.
Via Globe NewsWire
Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings
Via Benzinga
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
Via PressReach
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
From Small Pharma Inc.
Via Globe NewsWire
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
From Small Pharma Inc.
Via Globe NewsWire
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
From Small Pharma Inc.
Via Globe NewsWire
Comparing Psychedelics' Administration Routes: Are Intramuscular Injections More Effective Than Intravenous?
Via Benzinga
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
From Small Pharma Inc.
Via Globe NewsWire
Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More
Via Benzinga
This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage
Via Benzinga
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
From Small Pharma Inc.
Via Globe NewsWire
Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing
Via Benzinga
How Certain Psychedelics Produce Brain And Behavior Changes: UCL Leads New Study
Via Benzinga
First Patient Dosed in Small Pharma’s Drug Interaction Study
From Small Pharma Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.